Anti-Inflammatory Lipid Nanoparticles Derived from Kaempferol: A Dual- Functional mRNA Delivery Platform for Lung Cancer Therapy

The promise of messenger RNA, or mRNA, has transformed modern medicine, offering a way to instruct cells to build their own medicines. This technology relies on tiny, fat-based bubbles called lipid nanoparticles to carry the fragile genetic instructions safely into the body. While these particles have proven successful in vaccines, delivering them directly to the lungs through a mist remains a difficult challenge. The current methods often trigger a harsh immune reaction, causing inflammation that damages lung tissue, while simultaneously failing to get the genetic cargo out of the cell's internal recycling centers and into the main workspace where it is needed. Researchers are searching for a way to make these delivery vehicles both gentler on the lungs and more efficient at releasing their payload.

A team of scientists has developed a new approach that addresses both problems at once by adding a natural plant compound called kaempferol to the lipid nanoparticles. Kaempferol is a substance found in many fruits and vegetables, known for its ability to calm inflammation. By mixing this compound into the fat bubbles used for delivery, the researchers created a dual-purpose platform. In tests on mice, the new particles, which the team calls "Kaesomes," significantly reduced the swelling and immune cell invasion that typically follows lung misting. At the same time, the addition of kaempferol changed the physical structure of the particles, allowing them to escape the cell's internal traps much more effectively than standard versions.

The researchers found that when they adjusted the recipe to include a specific type of fat that helps membranes fuse, the particles became even more powerful. These optimized particles, containing five percent kaempferol, showed a unique shape that resembled budding vesicles rather than the layered, onion-like structure of traditional particles. This structural change allowed them to linger longer in the lungs and enter cells more readily. In laboratory tests using human lung cancer cells, these particles delivered genetic instructions nine times more effectively than the standard method. They successfully delivered instructions to produce a tumor-suppressing protein called p53, which killed the cancer cells while causing far less inflammation than the unmodified particles.

When tested in a model of lung cancer metastasis, the optimized particles delivered the therapeutic instructions to the tumors with high precision, leading to significant tumor shrinkage and cell death. Crucially, this powerful effect came without the severe toxicity usually associated with such treatments. The animals treated with the new particles showed no signs of damage to their major organs, and their immune systems remained calm. By integrating a natural anti-inflammatory agent directly into the delivery vehicle, the researchers have demonstrated a way to bypass the usual trade-off between safety and effectiveness. This strategy suggests a path forward for inhalable therapies that can treat lung diseases without causing the collateral damage that has long hindered their development.